Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-01-20

Clinical Trial Update: Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials [Phase 3]

View source ↗

Summary

Open-label, multi-site extension study in Chronic Hand Eczema patients who completed the DELTA 1 or DELTA 2 Phase 3 trials; results were posted on 2025-01-20.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • delgocitinib (delgocitinib)

Snippet

Sponsor: LEO Pharma | Conditions: Chronic Hand Eczema | Phase 3 | Status: COMPLETED | Results posted: 2025-01-20